The Impact of Limited Insurance Coverage on Long-Term Persistence with Anti-CGRP Monoclonal Antibody Therapy: A Multicenter Real-World Study in Korea
Headache and Pain Research · 30.06.2026 · 27 (2) · 145-153
DOI: 10.62087/hpr.2026.0007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache and Pain Research, erschienen am 30.06.2026. Verfasst von Mi-Kyoung Kang und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korean Headache Society.
Abstract (Originalsprache)
Purpose
Anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) are effective preventive therapies for migraine. However, their high cost limits long-term use. In Korea, coverage of anti-CGRP mAbs by the National Health Insurance Service (NHIS) is highly restricted. This study aimed to evaluate the association between NHIS coverage and treatment persistence in a real-world setting.
Methods
This retrospective multicenter study included adult patients with migraine (≥18 years) who received anti-CGRP mAb therapy at four tertiary hospitals in Korea. Treatment compliance was assessed using persistence, defined as continuous treatment duration; persistence rates; and adherence, defined as the proportion of days covered. Reasons for treatment discontinuation were also analyzed. Treatment compliance was compared according to NHIS coverage, and treatment effectiveness was compared according to NHIS coverage and treatment continuation.
Results
Among 140 patients treated with anti-CGRP mAbs, only 12 (8.6%) received NHIS-covered therapy. Compared with the non-covered group, the NHIS-covered group had a lower discontinuation rate (50.0% [6/12] vs. 73.4% [94/128]; p=0.101) and higher persistence rates at 6 months (80.0% vs. 66.0%; p=0.493) and 12 months (66.7% vs. 47.2%; p=0.312). However, these differences were not statistically significant. Treatment effectiveness, assessed by changes in monthly headache days, did not differ significantly according to NHIS coverage or treatment continuation.
Conclusion
Treatment persistence appears to be influenced by multiple factors in real-world practice. NHIS coverage may support treatment continuation by improving access and reducing the financial burden. These findings highlight the importance of healthcare-system factors in optimizing long-term preventive treatment strategies for migraine.
Förderung
- Korean Headache Society
Zitieren
APA
Kang, M., Sohn, J., Cha, M., Kim, Y. H., Hong, Y., Im, H., & Cho, S. (2026). The Impact of Limited Insurance Coverage on Long-Term Persistence with Anti-CGRP Monoclonal Antibody Therapy: A Multicenter Real-World Study in Korea. Headache and Pain Research, 27(2), 145-153. https://doi.org/10.62087/hpr.2026.0007
Vancouver
Kang M, Sohn J, Cha M, Kim YH, Hong Y, Im H, et al. The Impact of Limited Insurance Coverage on Long-Term Persistence with Anti-CGRP Monoclonal Antibody Therapy: A Multicenter Real-World Study in Korea. Headache and Pain Research. 2026;27(2):145-153. doi:10.62087/hpr.2026.0007
BibTeX
@article{Kang2026,
author = {Kang, Mi-Kyoung and Sohn, Jong-Hee and Cha, Myoung-Jin and Kim, Yoo Hwan and Hong, Yooha and Im, Hee-Jin and Cho, Soo-Jin},
title = {The Impact of Limited Insurance Coverage on Long-Term Persistence with Anti-CGRP Monoclonal Antibody Therapy: A Multicenter Real-World Study in Korea},
journal = {Headache and Pain Research},
year = {2026},
volume = {27},
number = {2},
pages = {145--153},
doi = {10.62087/hpr.2026.0007}
}
EUVIMED